Phaseline

Targets › DMD

DMD (Dystrophin): drug programs, companies and trials

16 programs from 13 companies in 22 trials: 9 Phase 1, 6 Phase 3, 5 Phase 2, 2 Phase 4; Neurology, Psychiatry, Hematology; next expected readout Nov 2026.

Anchors the extracellular matrix to the cytoskeleton via F-actin. Ligand for dystroglycan. (UniProt, P11532)

Open in Phaseline: the race on DMD, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sarepta Therapeuticsdelandistrogene moxeparvovec
Dystrophin exogenous gene
DMDPhase 4Duchenne Muscular DystrophyMay 2027
NS PharmaViltolarsen
Dystrophin pre-mRNA positive modulator
DMDPhase 4Duchenne Muscular DystrophySep 2032
Avidity BiosciencesAOC 1044
antisense oligonucleotide for exon 44 skipping
DMDPhase 3Muscular Dystrophies; DMDApr 2027
Solid BiosciencesSGT-003
Adeno-associated virus serotype SLB101 gene therapy delivering human microdystrophin gene
DMDPhase 3Duchenne Muscular DystrophyMay 2027
Dyne TherapeuticsZeleciment Rostudirsen (DYNE-251)
Antisense oligonucleotide for exon 51 skipping
DMDPhase 3Duchenne Muscular Dystrophy (DMD)Dec 2030
Sarepta TherapeuticsEteplirsen
Dystrophin pre-mRNA positive modulator
DMDPhase 3Muscular Dystrophy, Duchenne–
NS PharmaNS-089/NCNP-02
Exon 44 skipping agent
DMDPhase 2Duchenne Muscular DystrophyFeb 2027
Nippon ShinyakuNS-089/NCNP-02 (Brogidirsen)
Antisense oligonucleotide targeting DMD exon 45 skip
DMDPhase 2Duchenne Muscular Dystrophy (DMD)Apr 2027
REGENXBIORGX-202
Recombinant AAV8 gene therapy delivering novel microdystrophin transgene with C-terminal d
DMDPhase 2Duchenne Muscular DystrophyJun 2028
GenethonGNT0004
AAV8-delivered sequence-optimized microdystrophin gene therapy
DMDPhase 2Duchene Muscular DystrophyOct 2028
Solid BiosciencesSGT-001
AAV9 vector-mediated microdystrophin gene transfer
DMDPhase 1Duchenne Muscular DystrophyNov 2026
Wave Life Sciences USAWVE-N531
Antisense oligonucleotide (ASO) targeting exon 53 skipping in DMD
DMDPhase 1Duchenne Muscular DystrophyApr 2027
Belief BioMed (Beijing)BBM-D101
AAV-mediated gene addition therapy delivering dystrophin-associated protein complex therap
DMDPhase 1DMDJun 2027
Insmed Gene TherapyINS1201
Gene therapy for Duchenne muscular dystrophy
DMDPhase 1Duchenne Muscular DystrophyJan 2028
AO GENERIUMGNR-097
AAV9-delivered truncated dystrophin gene therapy (micro-dystrophin)
DMDPhase 1Duchenne Muscular DystrophyAug 2029
Precision BioSciencesPBGENE-DMD
Ex vivo gene editing therapy targeting DMD mutations amenable to exons 45-55 excision
DMDPhase 1Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMDNov 2029

Conditions

Duchenne Muscular Dystrophy (13) Duchenne Muscular Dystrophy (DMD) (3) DMD (2) Duchene Muscular Dystrophy (1) Muscular Dystrophies (1) Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD (1) Muscular Dystrophy, Duchenne (1)

Modalities

other (13), small molecule (2), protein or peptide (1)

Companies

Solid Biosciences (2) NS Pharma (2) Sarepta Therapeutics (2) Genethon (1) Dyne Therapeutics (1) Avidity Biosciences (1) REGENXBIO (1) Precision BioSciences (1) Wave Life Sciences USA (1) Belief BioMed (Beijing) (1) Insmed Gene Therapy (1) Nippon Shinyaku (1) AO GENERIUM (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.